SOURCE: Cambridge Healthtech Associates

April 07, 2011 07:00 ET

MetaMap® Tox -- A Novel Technology for Early Safety Enablement in Pharmaceutical Development Will Be Validated by Industry Consortium

Cambridge Healthtech Associates and Metanomics Health GmbH Announce a Collaborative Technology Evaluation

NEEDHAM, MA and BERLIN--(Marketwire - April 7, 2011) - The Drug Safety Executive Council (DSEC), an industry membership run by Cambridge Healthtech Associates (CHA), together with Metanomics Health GmbH, a BASF Group company, and leader in offering targeted and non-targeted metabolite profiling to healthcare customers, today announced a new project as part of DSEC's Technology Evaluation Consortium.

The goal of the project is to assess the scientific and economic utility of MetaMap® Tox, a platform that uses metabolite patterns of rat plasma for early recognition of toxicity for new drugs. Nine leading biopharmaceutical companies, whose names are undisclosed, will participate in the collaborative evaluation of MetaMap® Tox.

"The MetaMap® Tox solution is an exciting new tool to assess the safety of a compound in the development phase. This project supports CHA's mission of streamlining the research and development process," said Eric Glazer, Managing Director, DSEC.

"MetaMap® Tox offers the unique possibility to monitor systemic toxicological response of rats to new chemical entities based on > 100 established specific metabolic patterns indicative for toxicological modes of action. The benefit is to better and earlier identify the potential safety risks for a test compound and help guiding steps to mitigate risk in early drug development," said Tim Boelke, Managing Director, Metanomics Health GmbH. "We are therefore excited that Metanomics Health is one of a select few technology providers invited to participate in the DSEC Technology Evaluation Consortium."

About Cambridge Healthtech Associates and the Drug Safety Executive Council
CHA is the leading organizer of consortia in life sciences. CHA reduces the costs of R&D by bringing companies together to work cooperatively. The Technology Evaluation Consortium determines the scientific utility of predictive safety technologies by leveraging the expertise of biopharmaceutical companies. CHA also manages DSEC, an online, peer membership of over 2,000 drug safety leaders. Learn more at www.chacorporate.com and www.drugsafetycouncil.org. CHA is wholly owned by Cambridge Healthtech Institute (CHI).

About Metanomics Health GmbH
Metanomics Health GmbH, a BASF Group company, was founded in 2003 and is the world leading company offering robust targeted and non-targeted comprehensive metabolite profiling services (metabolomics) to healthcare customers. Serving pharma, nutrition, diagnostics companies and academic partners, the state-of-the-art biomedical data interpretation with innovative bioinformatics and data mining systems, enables discovery and validation of both, simple and complex metabolomic biomarkers. Metanomics Health delivers novel biomarkers of disease and drug efficacy, increased mechanistic understanding of drug action and adverse effects as well as insights into underlying pathways to its partners, thereby providing actionable results for healthcare research and development programs. Learn more at www.metanomics-health.de

Contact Information

  • CONTACT:

    Drug Safety Executive Council (DSEC)
    Contact:
    Eric Glazer
    Tel: + 1 (781) 972-5498
    Email: Email Contact

    Metanomics Health GmbH

    United States:
    Contact:
    Christopher Macri
    Tel: +1 (201) 683-8183
    Email: Email Contact

    Europe/Asia:
    Contact:
    Niels Moller
    Tel: +49 (0)30-34-807-400
    Email: Email Contact